⌘K
Loading ticker…
As of 2026-08-24, Grace Therapeutics, Inc. Common Stock (GRCE) has a 3-month relative strength percentile of 46 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 41. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.2%, relative volume 0.34×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
GRCE is in a stage 4 downtrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -4.1% / -30.0%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
GRCE appears in 1 ETF as of Mar 2026: VTI at 0.00% weight, $2M notional.
Held by 1 ETFs · $2M across latest filings · largest weight 0.00% (VTI).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $2M | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GRCE Jan avg: -3.43% median: -3.43% win: 50% σ: 11.79% n: 2 2024-10-29 → 2026-07-31 | GRCE Feb avg: 5.00% median: 5.00% win: 50% σ: 18.64% n: 2 2024-10-29 → 2026-07-31 | GRCE Mar avg: -8.41% median: -8.41% win: 50% σ: 23.11% n: 2 2024-10-29 → 2026-07-31 | GRCE Apr avg: -18.57% median: -18.57% win: 50% σ: 46.73% n: 2 2024-10-29 → 2026-07-31 | GRCE May avg: 10.49% median: 10.49% win: 100% σ: 6.00% n: 2 2024-10-29 → 2026-07-31 | GRCE Jun avg: -2.28% median: -2.28% win: 50% σ: 13.28% n: 2 2024-10-29 → 2026-07-31 | GRCE Jul avg: -5.53% median: -5.53% win: 0% σ: 4.01% n: 2 2024-10-29 → 2026-07-31 | GRCE Aug avg: 4.84% median: 4.84% win: 100% σ: 0.00% n: 1 2024-10-29 → 2026-07-31 (current) | GRCE Sep avg: -1.75% median: -1.75% win: 0% σ: 0.00% n: 1 2024-10-29 → 2026-07-31 | GRCE Oct avg: 2.83% median: 2.83% win: 50% σ: 4.45% n: 2 2024-10-29 → 2026-07-31 | GRCE Nov avg: 2.90% median: 2.90% win: 100% σ: 2.97% n: 2 2024-10-29 → 2026-07-31 | GRCE Dec avg: 10.06% median: 10.06% win: 100% σ: 1.77% n: 2 2024-10-29 → 2026-07-31 |